Biotech companies at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
38 biotech companies are at ESMO 2026 — 4 presentations on the program and 37 with a booth in the exhibit hall. Most represented: Avacta (1 on the program). 37 of them have their own page in this guide. As of Sep 29, 2026.
Tumour type
Top represented
Showing 1–19 of 38 organizations
| Organization | ESMO 2026 Attendance |
|---|---|
Avacta London, United Kingdom | |
UK biotech developing pre|CISION tumour-activated peptide drug conjugates. | Satellite Sat Oct 24 10:20–10:40 |
Oncology division of German radiopharmaceutical company ITM, developing targeted radioligand therapies for cancers such as neuroendocrine tumours. | Booth Exhibiting at Booth 1024 Satellite Mon Oct 26 18:30–20:00 |
Spanish biopharmaceutical company developing and marketing marine-derived cancer medicines, including trabectedin and lurbinectedin. | Booth Exhibiting at Booth 1066 Satellite Sat Oct 24 18:30–20:00 PharmaMar - More time for patients: Reframing the course of ES-SCLC Lung & thoracic cancers |
US oncology company developing RAS(ON) inhibitors, such as daraxonrasib, for RAS-driven cancers including pancreatic and lung cancer. | Booth Exhibiting at Booth 8036 Satellite Mon Oct 26 18:30–20:00 Revolution Medicines - Advances in RAS-targeted therapies: emerging clinical data and future directions in NSCLC and PDAC Lung & thoracic cancersGastrointestinal cancers |
Akeso Zhongshan, China | |
Chinese biopharma developing bispecific antibodies, including ivonescimab (PD-1/VEGF) and cadonilimab (PD-1/CTLA-4). | Booth Exhibiting at Booth 1052 |
Clinical-stage biotech developing firmonertinib for EGFR-mutant non-small cell lung cancer. | Booth Exhibiting at Booth 8111 |
Clinical-stage biotech developing ficerafusp alfa, an EGFR/TGF-beta bifunctional antibody, for head and neck cancer. | Booth Exhibiting at Booth 8012 |
BioNTech Mainz, Germany | |
German biotech developing mRNA cancer immunotherapies, antibody-drug conjugates and bispecific antibodies. | Booth Exhibiting at Booth 8070 |
Celcuity Minneapolis, MN | |
Clinical-stage biotech developing gedatolisib, a PI3K/mTOR inhibitor, for HR-positive, HER2-negative advanced breast cancer. | Booth Exhibiting at Booth 1028 |
Cogent Biosciences Waltham, MA | |
Biotech developing bezuclastinib, a selective KIT inhibitor, for systemic mastocytosis and gastrointestinal stromal tumours. | Booth Exhibiting at Booth 8109 |
Compass Therapeutics Boston, MA | |
Clinical-stage biotech developing tovecimig, a DLL4/VEGF-A bispecific antibody, for biliary tract cancer. | Booth Exhibiting at Booth 8114 |
Corcept Therapeutics Menlo Park, CA | |
Develops cortisol modulators, including relacorilant for platinum-resistant ovarian cancer. | Booth Exhibiting at Booth 1016 |
Biotech developing PD-1/VEGF bispecific antibodies and antibody-drug conjugates for solid tumours. | Booth Exhibiting at Booth 8011 |
Deciphera Pharmaceuticals Waltham, MA | |
Kinase-inhibitor developer behind ripretinib for GIST and vimseltinib for tenosynovial giant cell tumour; owned by Ono Pharmaceutical. | Booth Exhibiting at Booth 1074 |
Biotech developing rivoceranib plus camrelizumab for hepatocellular carcinoma; a subsidiary of Korea's HLB. | Booth Exhibiting at Booth 1085 |
Exelixis Alameda, CA | |
US oncology company developing small-molecule cancer drugs, including cabozantinib (Cabometyx). | Booth Exhibiting at Booth 1014 |
US precision oncology biotech developing targeted therapies such as plixorafenib for BRAF-altered cancers. | Booth Exhibiting at Booth 1096 |
US-based member of the Innovent Biologics group, developing antibody-drug conjugates and bispecific antibodies for cancer outside China. | Booth Exhibiting at Booth 1076 |
Danish biotech developing antibody therapies for cancer, including bispecific antibodies and antibody-drug conjugates. | Booth Exhibiting at Booth 8022 |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESMO 2026 by
Organization type
Tumour type
Exhibit hall
Everyone
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction